CDSCO Mandates Indian Licensing for Medical Device Procurement

The Central Drugs Standard Control Organization (CDSCO) has issued a Circular dated November 17, 2025, to all procurement agencies, including hospitals and health institutions, mandating that a valid license issued by CDSCO or the State Licensing Authority (SLA) must be a compulsory requirement for the procurement of Medical Devices in India.

State Lab Issues Alert for Spurious Dry Cough Formula

The State Drug Testing Laboratory (SDTL) in Raipur, Chhattisgarh, has flagged a batch of the product Besto-Cof DRY COUGH FORMULA as purported to be spurious. The actual manufacturer, as per the label claim, has officially stated that the impugned batch was not manufactured by them, confirming the product’s status as spurious and subject to the outcome of an ongoing investigation.

Nationwide Alert Issued as 112 Drug Batches Declared Not of Standard Quality in September 2025

The Central Drugs Standard Control Organisation (CDSCO) and various State Drug Testing Laboratories have issued a comprehensive alert identifying numerous drug batches that failed quality testing in September 2025. The consolidated list comprises 112 instances of drug products—including antibiotics, cardiovascular medications, supplements, and specialized injections—that were declared Not of Standard Quality (NSQ).

CDSCO Publishes Extensive Draft Guidance for Medical Device Software Regulations

The Central Drugs Standard Control Organisation (CDSCO) has published a comprehensive draft Guidance Document on the regulatory requirements for Medical Device Software under the Medical Devices Rules (MDR), 2017. The guidance aims to harmonize India’s regulatory practices with global standards and bring clarity to the licensing, quality, and post-market surveillance of software used in healthcare.

CDSCO Invites Comments to Address Discrepancy in New Drug Approval Process

The Central Drugs Standard Control Organization (CDSCO) has issued a notice inviting comments from all stakeholders regarding a regulatory discrepancy that affects the cost and complexity of obtaining approval for a new drug in India. The move is intended to initiate discussions on establishing a level playing field and fostering domestic research and development (R&D).

Health Ministry Orders Nationwide Crackdown on Contaminated Cough Syrups and Irrational Use

The Union Ministry of Health and Family Welfare convened a high-level meeting under the chairmanship of Union Health Secretary to address recent concerns regarding the quality and administration of cough syrups, particularly in children. The meeting, attended by top officials from the Ministry of Health, Department of Pharmaceuticals, ICMR, and Drugs Controller General of India (DCGI), resulted in strict directives for all States and Union Territories.